Voltaren and Nephrogenic systemic fibrosis - a phase IV clinical study of FDA data

Summary:

Nephrogenic systemic fibrosis is reported as a side effect among people who take Voltaren (diclofenac sodium), especially for people who are female, 50-59 old, also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Nephrogenic systemic fibrosis when taking Voltaren. It is created by eHealthMe based on reports of 81,356 people who have side effects when taking Voltaren from the FDA, and is updated regularly.

What is Voltaren?

Voltaren has active ingredients of diclofenac sodium. It is often used in arthritis. eHealthMe is studying from 82,346 Voltaren users. Check the latest studies of Voltaren.

What is Nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease) is found to be associated with 503 drugs and 673 conditions by eHealthMe. Check the latest studies of Nephrogenic systemic fibrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

81,356 people reported to have side effects when taking Voltaren.
Among them, 23 people (0.03%) have Nephrogenic systemic fibrosis.

Could Voltaren cause Nephrogenic systemic fibrosis?

Among these 23 people:

What is the gender of people who have Nephrogenic systemic fibrosis when taking Voltaren? *

female: 52.17 %
male: 47.83 %

What is the age of people who have Nephrogenic systemic fibrosis when taking Voltaren? *

What are other drugs people take besides Voltaren? *

What are other side effects people have besides Nephrogenic systemic fibrosis? *

Skin Fibrosis (fibrous tissue formation on skin): 15 people, 65.22%
Skin Hypertrophy (skin cells enlarges): 14 people, 60.87%
Oedema Peripheral (superficial swelling): 14 people, 60.87%
Joint Pain: 13 people, 56.52%
Deformity (disfigurement): 12 people, 52.17%
Joint Range Of Motion Decreased (disease of joint movement): 12 people, 52.17%
Skin Discoloration: 12 people, 52.17%
Weakness: 12 people, 52.17%
Joint Contracture (a permanent shortening of a muscle or joint): 10 people, 43.48%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 9 people, 39.13%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 8 people, 34.78%
Asthma: 7 people, 30.43%
Blood Phosphorus Increased: 5 people, 21.74%
Tumor: 2 people, 8.70%
Thyroid Cancer: 2 people, 8.70%
Oedema Peripheral (superficial swelling): 2 people, 8.70%
Joint Swelling: 2 people, 8.70%
Depression: 2 people, 8.70%
Blood Pressure Abnormal: 2 people, 8.70%
Back Pain: 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Voltaren and have Nephrogenic systemic fibrosis?

- Check whether Nephrogenic systemic fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Voltaren:

Voltaren (82,346 reports)

Browse all side effects of Voltaren:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (503 drugs)

Browse all the conditions that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (673 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diclofenac sodium (the active ingredients of Voltaren) and Voltaren (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.